The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โABBVโ.
As of April 2024 AbbVie has a market cap of $287.07 Billion. This makes AbbVie the world's 34th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Year | Market cap | Change |
---|---|---|
2024 | $287.07 B | 4.92% |
2023 | $273.60 B | -4.27% |
2022 | $285.80 B | 19.4% |
2021 | $239.37 B | 26.54% |
2020 | $189.17 B | 44.47% |
2019 | $130.94 B | -3.95% |
2018 | $136.33 B | -11.7% |
2017 | $154.39 B | 51.71% |
2016 | $101.76 B | 6.7% |
2015 | $95.37 B | -8.42% |
2014 | $104.14 B | 24.23% |
2013 | $83.82 B | 55.32% |
2012 | $53.97 B |
On Apr 25th, 2024 the market cap of AbbVie was reported to be:
Name | Market cap | Market cap differencediff. | Country |
---|---|---|---|
Pfizer PFE | $143.63 B | -49.97% | ๐บ๐ธ USA |
Eli Lilly LLY | $696.83 B | 142.74% | ๐บ๐ธ USA |
Amgen AMGN | $145.21 B | -49.41% | ๐บ๐ธ USA |
Biogen BIIB | $30.12 B | -89.51% | ๐บ๐ธ USA |
Gilead Sciences GILD | $81.66 B | -71.55% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $91.48 B | -68.13% | ๐บ๐ธ USA |
AstraZeneca AZN | $232.39 B | -19.05% | ๐ฌ๐ง UK |
GlaxoSmithKline GSK | $83.84 B | -70.79% | ๐ฌ๐ง UK |
Neurocrine Biosciences
NBIX | $13.68 B | -95.23% | ๐บ๐ธ USA |